4.65
1.31%
+0.06
Relmada Therapeutics Inc stock is currently priced at $4.65, with a 24-hour trading volume of 113.40K.
It has seen a +1.31% increased in the last 24 hours and a -24.27% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $4.62 pivot point. If it approaches the $4.84 resistance level, significant changes may occur.
Relmada Therapeutics Inc Stock (RLMD) Financials Data
Relmada Therapeutics Inc (RLMD) Net Income 2023
RLMD net income (TTM) was -$111.57 million for the quarter ending September 30, 2023, a +27.30% increase year-over-year.
Relmada Therapeutics Inc (RLMD) Cash Flow 2023
RLMD recorded a free cash flow (TTM) of -$77.29 million for the quarter ending September 30, 2023, a +26.79% increase year-over-year.
Relmada Therapeutics Inc (RLMD) Earnings per Share 2023
RLMD earnings per share (TTM) was -$3.70 for the quarter ending September 30, 2023, a +36.64% growth year-over-year.
Relmada Therapeutics Inc Stock (RLMD) Latest News
About Relmada Therapeutics Inc
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, is being developed as a rapidly acting, oral agent for the treatment of depression, neuropathic pain, and/or other potential CNS pathological conditions. The company is also developing LevoCap ER, an extended release, abuse deterrent, and proprietary formulation of the opioid analgesic levorphanol for the treatment of pain; BuTab, a formulation of oral, modified release buprenorphine for chronic pain and opioid dependence; and MepiGel, a proprietary topical dosage form of the local anesthetic mepivacaine for the treatment of painful peripheral neuropathies, such as painful diabetic neuropathy, postherpetic neuralgia, and painful HIV-associated neuropathy. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in New York, New York.
Cap:
|
Volume (24h):